Search results for #MMSM
🚨 Time is running out to sign up for our Patient Webinar happening TOMORROW! Learn how the #myeloma care team determines if you are a candidate for ASCT, what the procedure consists of, and why it’s used in treating #multiplemyeloma. Register now: ow.ly/GMBj50Rkaoy #mmsm
Check our recent publication: B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma #mmsm ➡️onlinelibrary.wiley.com/doi/full/10.10… Talquetamab 1st➡️BCMA BsAb or CAR-T ✅Median F/U:9.5 months(range:6–24mo) ✅Median PFS: 5.5 months (range:1–10mo)
RAS/RAF landscape in monoclonal plasma cell conditions [Apr 21, 2024] @ASchavgoulidze et al. @BloodJournal ashpublications.org/blood/article/… #mmsm #PrecisionMedicine #caxtx HT @Myeloma_Doc
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma [Feb 8, 2022] Anderson et al. @BloodJournal ow.ly/PNLE50HSCzc #mmsm #PrecisionMedicine #ImmunoOnc
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma [Mar 31, 2022] @nikos_trasan et al. @BloodJournal ow.ly/vkRH50IA1i3 #mmsm #PrecisionMedicine [THREAD]: x.com/nikos_trasan/s…
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma [Mar 31, 2022] @nikos_trasan et al. @BloodJournal ow.ly/vkRH50IA1i3 #mmsm #PrecisionMedicine [THREAD]: x.com/nikos_trasan/s…
Genomic Classification and Individualized Prognosis in Multiple Myeloma [Jan 9, 2024] @FrancescoMaura4 et al. @DrOlaLandgren @JCO_ASCO ascopubs.org/doi/10.1200/JC… #mmsm #PrecisionMedicine #IRMMa & Dr. Maura Thread: x.com/francescomaura…
Genomic Classification and Individualized Prognosis in Multiple Myeloma [Jan 9, 2024] @FrancescoMaura4 et al. @DrOlaLandgren @JCO_ASCO ascopubs.org/doi/10.1200/JC… #mmsm #PrecisionMedicine #IRMMa & Dr. Maura Thread: x.com/francescomaura… https://t.co/74mvHwS1NP
Especially not great in the context of pts receiving len maintenance. This deserves sone further thought as we continue to define the role of #bmt in MM. #mmsm
Please join us For a @theMMRF and @IcahnMountSinai Patient Summit. @TischCancer. #mmsm Saturday, May 4, 2024 8:00 AM–12:30 PM (ET) event.webcasts.com/viewer/share.j…
#mmsm @theMMRF With MRD as early endpoint for accelerated approval of new multiple myeloma drugs, patients' access to new therapies will be much quicker. Instead of waiting for 10-15 yrs, new drugs can be available in 3-5 yrs. Here is how it works: vjhemonc.com/video/mzdrxxne…
Carfilzomib-associated renal toxicity in 17% of patients; 5% had TMA albuminuria >1 gr/day in 6% and G 3 AKI 5%! #mmsm #MedTwitter @OncoAlert @USMIRCNEWS #USMIRC #MedEd #myeloma #Oncology
I couldn’t agree more! Thank you @MyelomaTeacher for providing an important patient perspective for MRD negativity as a surrogate endpoint in #myeloma clinical trials! #mmsm
I couldn’t agree more! Thank you @MyelomaTeacher for providing an important patient perspective for MRD negativity as a surrogate endpoint in #myeloma clinical trials! #mmsm
Treg depletion supercharges ASCT power ashpublications.org/blood/article/… #mmsm #USMIRC @USMIRCNEWS #MedEd #medtwitter @ASH_hematology
Brilliant commentary for physicians by @MyelomaTeacher about MRD negativity in #MMsm 👏 She illustrates importance of involving patients in our decision-making despite uncertainties therein. FDA’s call was correct, and no surprise that Cindy’s hashtag is “Myeloma Teacher”!
Brilliant commentary for physicians by @MyelomaTeacher about MRD negativity in #MMsm 👏 She illustrates importance of involving patients in our decision-making despite uncertainties therein. FDA’s call was correct, and no surprise that Cindy’s hashtag is “Myeloma Teacher”! https://t.co/hUbLOLJBuw
WATCH: Adam D. Cohen, MD, discusses ongoing research influencing the multiple #myeloma treatment landscape. #MMSM | @PennMedicine targetedonc.com/view/car-t-and…
Here is a blog I wrote about why I feel MRD negativity should be used as a surrogate endpoint in #myeloma clinical trials. MRD as a Clinical Trial Endpoint: A Patient Perspective healthtree.org/myeloma/commun… #MMSM
European Commission Approves Cilta-Cel for R/R Myeloma After at Least 1 Prior Line of Therapy @unav #mmsm onclive.com/view/european-…